Skip to main content

Table 3 Subgroup analysis

From: Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis

Outcomes Group RR (95% CI) P value P value for heterogeneity
Resectability Country
Asian 1.23 (1.04–1.46) 0.015 0.243
Europe 1.00 (0.91–1.11) 0.950 0.008
Mean age (years)
60 or more 1.02 (0.81–1.29) 0.842 0.002
< 60 1.29 (0.84–1.97) 0.251 < 0.001
Percentage male (%)
70 or greater 1.13 (0.87–1.46) 0.355 < 0.001
< 70 1.14 (0.91–1.42) 0.257 0.020
Percentage of tumor stage (I and II) (%)
30 or greater 0.99 (0.83–1.18) 0.934 0.009
< 30 1.22 (0.94–1.59) 0.132 0.001
Disease status
Gastroesophageal cancer 1.02 (0.81–1.29) 0.842 0.002
Gastric cancer 1.12 (0.96–1.31) 0.136 0.018
OS Country
Asian
Europe 0.74 (0.63–0.88) 0.001 0.792
Mean age (years)
60 or more 0.73 (0.61–0.88) 0.001 0.674
< 60 0.84 (0.52–1.35) 0.474
Percentage male (%)
70 or greater 0.73 (0.61–0.88) 0.001 0.674
< 70 0.84 (0.52–1.35) 0.474
Percentage of tumor stage (I and II) (%)
30 or greater 0.73 (0.61–0.88) 0.001 0.674
< 30 0.84 (0.52–1.35) 0.474
Disease status
Gastroesophageal cancer 0.73 (0.61–0.88) 0.001 0.674
Gastric cancer 0.84 (0.52–1.35) 0.474
PFS Country
Asian
Europe 0.67 (0.57–0.79) < 0.001 0.825
Mean age (years)
60 or more 0.66 (0.55–0.78) < 0.001 0.936
< 60 0.76 (0.49–1.17) 0.212
Percentage male (%)
70 or greater 0.66 (0.55–0.78) < 0.001 0.936
< 70 0.76 (0.49–1.17) 0.212
Percentage of tumor stage (I and II) (%)
30 or greater 0.66 (0.55–0.78) < 0.001 0.936
< 30 0.76 (0.49–1.17) 0.212
Disease status
Gastroesophageal cancer 0.66 (0.55–0.78) < 0.001 0.936
Gastric cancer 0.76 (0.49–1.17) 0.212